Genmab

Genmab's reported carbon emissions

Genmab, a pharmaceutical preparation manufacturing company headquartered in Denmark, is actively engaged in climate action, as evidenced by its comprehensive emissions reporting and reduction targets. For the reporting year 2024, Genmab reported a total of approximately 190 million kg CO2e in absolute emissions. This figure is composed of approximately 534,000 kg CO2e for Scope 1 emissions, approximately 1.7 million kg CO2e for Scope 1 and 2 market-based emissions, and a substantial portion of approximately 188 million kg CO2e attributed to Scope 3 emissions. Within Scope 3, the largest contributors were purchased goods and services, accounting for approximately 164 million kg CO2e, followed by business travel at approximately 10.6 million kg CO2e. In the preceding year, 2023, Genmab's total emissions amounted to approximately 151 million kg CO2e. This included approximately 317,000 kg CO2e in Scope 1 emissions and approximately 555,000 kg CO2e for Scope 1 and 2 market-based emissions. Scope 3 emissions for 2023 were approximately 151 million kg CO2e, with purchased goods and services being the primary driver at around 127 million kg CO2e. For the 2022 reporting year, Genmab's total emissions were approximately 148 million kg CO2e, encompassing approximately 283,000 kg CO2e for Scope 1 and approximately 111,000 kg CO2e for Scope 2 emissions. Scope 3 emissions for this period totalled approximately 147 million kg CO2e. Genmab has publicly committed to significant emission reductions, including a target for its suppliers (Scope 3, category 1) to reduce greenhouse gas emissions by 50% by 2030, using a 2019 baseline. While specific targets for Scope 1 and 2 emissions are not detailed in the provided information, the company's commitment to transparent reporting across all scopes indicates a strategic approach to managing its climate impact. The company's environmental reporting is documented in its sustainability reports, accessible via provided URLs.